SEC Form 4 · accession 0001493152-26-033972
Cingulate Inc. · CING
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Shane J. Schaffer
Officer — Chief Executive Officer · Director
Period of report
Jul 16, 2026
Accepted (ET)
Jul 20, 2026 · 7:37 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001862150
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to Buy)F1 | $4.43 | Jul 16, 2026 | A | 197,650 | A | — | Jul 16, 2036 | Common Stock | 197,650 | 197,650 | D |
| Stock Option (right to Buy)F1,F2,F3 | $4.43 | Jul 16, 2026 | A | 97,350 | A | — | Jul 16, 2036 | Common Stock | 97,350 | 97,350 | D |
Explanation of responses
- F1The option vests as follows: 25% on March 31, 2027 and the remaining shares in substantially equal monthly installments over the 36-month period following the initial vesting date.
- F2Vested option only becomes exercisable if the Issuer's NDA for CTx-1301 is approved by the FDA during 2027.
- F3If the Issuer's NDA for CTx-1301 is not approved by the FDA during 2027, the option, including any vested portion, shall terminate.